High‐dose sodium‐glucose co‐transporter‐2 inhibitors are superior in type 2 diabetes: A meta‐analysis of randomized clinical trials
Diabetes, Obesity and Metabolism — Shi FH, Li H, Shen L, et al. | June 24, 2021
This study sought to ascertain the overall efficacy of high- versus low-dose sodium-glucose co-transporter-2 (SGLT2) inhibitors in patients with type 2 diabetes (T2D). Researchers carried out searches of MEDLINE, EMBASE and the Cochrane Library between 1 January 2006 to 23 September 2020. They used random effects models to estimate mean differences and pooled relative risk. They carried out prespecified subgroup analyses for each SGLT2 inhibitor, follow-up and controls. Furthermore, leave-one-out sensitivity and meta-regression analyses were performed. The study enrolled a total of 51 randomized controlled trials including a total of 23,989 participants (weighted mean age, 58.9 years; men, 58.8%) for the meta-analysis. The findings suggest that overall effectiveness of SGLT2 inhibitors, mainly canagliflozin, dapagliflozin and empagliflozin, was found to be dose dependent.